1-3 of 3
Anne Keating
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia

Jing Chen, Cynthia A. Pise-Masison, Joanna H. Shih, John C. Morris, John E. Janik, Kevin C. Conlon, Anne Keating, Thomas A. Waldmann
Journal: Blood
Blood (2013) 121 (11): 2029–2037.
https://doi.org/10.1182/blood-2012-05-427773
Published: 2013
Includes: Supplemental data
Journal Articles

A Phase II Study of Sepantronium Bromide (YM155) Plus Rituximab in Previously Treated Subjects with Aggressive CD20-Positive B Cell Non-Hodgkin's Lymphoma Who Are Ineligible for or Have Previously Received an Autologous Stem Cell Transplant - Stage I Results.

Kyriakos P Papadopoulos, MD, Scott E. Smith, MD, PhD, Joyce Steinberg, MD, Renelle Papa, Javier Lopez-Jimenez, MD, Anne Keating, PharmD, Antoine Thyss
Journal: Blood
Blood (2012) 120 (21): 2731.
https://doi.org/10.1182/blood.V120.21.2731.2731
Published: 2012
Journal Articles

Efficacy and Safety of YM155 in Relapsed/Refractory Non-Hodgkin’s Lymphoma Patients Enrolled in a Phase I Study.

Kyriakos Papadopoulos, MD, Alain Mita, MD, Scott Antonio, MD, Lionel D. Lewis, MD, N.J. Reddy, Elizabeth Till, J.J. Mahany, Anne Keating, DPharm, Amanda Seiz, Pamela Bartels, Anthony Tolcher, MD
Journal: Blood
Blood (2007) 110 (11): 3422.
https://doi.org/10.1182/blood.V110.11.3422.3422
Published: 2007